Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 649-652, 2019.
Article
em Zh
| WPRIM
| ID: wpr-775577
Biblioteca responsável:
WPRO
ABSTRACT
As a new type of anti-cancer drugs, immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic effects in many malignant tumors. By virtue of their targets and mechanisms of action, ICIs can cause autoimmune and inflammatory effects, termed immune-related adverse events (irAEs). Unlike traditional therapies, irAEs are latent and unstable. Severe adverse reactions will force patients to discontinue treatment and even affect their survival. Therefore, with the wide application of ICIs in clinical practice, clinicians need to fully understand the possible adverse reactions of such drugs and appropriate treatment strategies, in order to improve the survival rate and treatment effect of patients receiving ICIs. In this article, we review the incidence, clinical features, diagnosis and treatment of immune-related endocrine events that may occur with administration of ICIs.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Diagnostic_studies
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2019
Tipo de documento:
Article
País de publicação:
CHINA
/
CN
/
REPUBLIC OF CHINA